BIRC5 and neoplasm: BIRC5/Survivin expression was also previously used as a biomarker for pharmacokinetic/pharmacodynamic (PK/PD) activity of the Wnt pathway in circulating tumor cells in the first-in-human clinical trial of the second-generation CBP/β-catenin specific antagonist PRI-724 (39).